{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-055164","form_type":"8-K","ticker":"RLMD","cik":"0001553643","company_name":"RELMADA THERAPEUTICS, INC.","filed_at":"2026-05-12T21:00:09+00:00","discovered_at":"2026-05-12T21:02:00.405979+00:00","generated_at":"2026-05-12T21:04:01.373246+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Relmada reports Q1 2026 net loss of $19.1M; NDV-01 Phase 2 shows 95% CR rate; cash $234M through 2029","bullets":["NDV-01 12-month Phase 2 in high-risk NMIBC: 95% CR at any time, 76% durable CR; BCG-unresponsive: 94% CR, 80% durable.","Cash balance $234.0M as of March 31, 2026, expected to fund operations through 2029 after $160M PIPE in March.","Net loss $19.1M ($0.22/share) vs $17.6M ($0.58) Q1 2025; R&D expense $8.1M; G&A $11.4M.","Phase 3 RESCUE registrational program on track for mid-2026; provisional patent filed April 2026 with term to 2047.","Upcoming milestones: IND filing mid-2026, initial Phase 3 data by YE 2026, Sepranolone Phase 2 in Prader-Willi mid-2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-055164","json":"https://secwatch.observer/filing/0001213900-26-055164.json","markdown":"https://secwatch.observer/filing/0001213900-26-055164.md","text":"https://secwatch.observer/filing/0001213900-26-055164.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1553643/000121390026055164/0001213900-26-055164-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1553643/000121390026055164/ea0290414-8k_relmada.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-12T21:04:01.373246+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}